Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets

被引：0
|
作者：
Lovett-Racke, A. [1 ,2 ]
Liu, Y. [2 ]
Gormley, M. [2 ]
Wray, S. [3 ]
Racke, M. [4 ]
Shubin, R. [5 ]
Su, W. [6 ]
Eubanks, J. [6 ]
Fox, E. [7 ]
机构：
[1] Ohio State Univ, Microbial Infect & Immun, Columbus, OH 43210 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Hope Neurol, Knoxville, TN USA
[4] Ohio State Univ, Neurol, Columbus, OH 43210 USA
[5] Arcadia Neurol Ctr, Pasadena, CA USA
[6] TG Therapeut, New York, NY USA
[7] Cent Texas Neurol Consultants, Round Rock, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1158
引用
收藏
页码：609 / 610
页数：2
相关论文
共 39 条
  • [31] Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma
    Lunning, Matthew A.
    Vose, Julie M.
    Schreeder, Marshall T.
    Fowler, Nathan
    Nastoupil, Loretta J.
    Siddiqi, Tanya
    Blumel, Susan
    Pauli, Emily K.
    Cutter, Kathy
    Tse, Warner
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Vakkalanka, Swaroop
    Viswanadha, Srikant
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [32] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Coiffier, Bertrand
    Lepretre, Stephane
    Pedersen, Lars Moller
    Gadeberg, Ole
    Fredriksen, Henrik
    van Oers, Marinus H. J.
    Wooldridge, James
    Kloczko, Janusz
    Holowiecki, Jerzy
    Hellmann, Anrzej
    Walewski, Jan
    Flensburg, Mimi
    Petersen, Jorgen
    Robak, Tadeusz
    BLOOD, 2008, 111 (03) : 1094 - 1100
  • [33] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial
    Shi, Yuankai
    Qin, Yan
    Zang, Aimin
    Li, Yufu
    Yang, Yanli
    Hui Liu
    Gao, Sujun
    Wang, Xinghe
    Zhang, Weijing
    Jin, Zhengming
    Hui Zhou
    Wang Hua-Qing
    Min Wei
    BLOOD, 2022, 140 : 9482 - 9483
  • [34] A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma
    Brighton, Timothy
    Harrison, Simon J.
    Ghez, David
    Weiss, Brendan M.
    Kirsch, Andreas
    Magen, Hila
    Gironella, Mercedes
    Oriol, Albert
    Streetly, Matthew
    Qin, Xiang
    Bandekar, Rajesh
    Hu, Peter
    Qi, Ming
    Nemat, Sepideh
    Goldschmidt, Hartmut
    BLOOD, 2017, 130
  • [35] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial
    Shi, Yuankai
    Qin, Yan
    Song, Yongping
    Zhou, Keshu
    Zhou, Hui
    Jing, Hongmei
    Xiang, Ying
    Wang, Zhao
    Wang, Zhen
    Zang, Aimin
    Bai, Ou
    Li, Zhenyu
    Zhang, Huilai
    BLOOD, 2021, 138
  • [36] Efficacy fi cacy and safety of MIL62, a novel glycoengineered type II anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial
    Shi, Yuankai
    Zhou, Keshu
    Zhou, Hui
    Qin, Yan
    Jing, Hongmei
    Xiang, Ying
    Wang, Zhao
    Wang, Zhen
    Zang, Aimin
    Bai, Ou
    Li, Zhenyu
    Zhang, Huilai
    Song, Yongping
    Liang, Jinjin
    Wei, Min
    ECLINICALMEDICINE, 2024, 73
  • [37] A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis
    Vollmer, Timothy L.
    Wynn, Daniel R.
    Alam, M. Shamsul
    Valdes, Joaquin
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 181 - 191
  • [38] Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study
    Shi, Yuankai
    Zhang, Qing Yuan
    Hong, Xiaonan
    Wang, Zhen
    Gao, Yuhuan
    Zou, Liqun
    Cen, Hong
    Gui, Lin
    Li, Yufu
    Feng, Jifeng
    Wang, Zhao
    Zhang, Mingzhi
    Jin, Chuan
    Zhang, Weihua
    Hu, Jianda
    Zheng, Chengyun
    Zheng, Zhendong
    Zhang, Liling
    Chen, Shaoshui
    Huang, Yunhong
    Tang, Yun
    Gao, Yajie
    Hao, Miaowang
    Li, Xiaoling
    Chang, Chunkang
    Yang, Haiyan
    Wu, Hui
    Shen, Lida
    Ke, Xiaoyan
    Zhang, Liangming
    Xi, Yaming
    Yang, Linhua
    Xie, Liangzhi
    BLOOD, 2021, 138
  • [39] Once daily oral CHS-131, a novel PPARγ agonist, reduces both neuroinflammation and gray matter volume depletion in patients with relapsing-remitting multiple sclerosis: a randomized, placebo controlled double-blind, Phase 2b, multicenter study
    Weinstein, D.
    Boyko, A.
    Pugliese, L.
    Tang, H.
    Zivadinov, R.
    Lanfear, D.
    Finck, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 349 - 349
1234